ClinicalTrials.gg
CompletedNCT01831804Updated Aug 19, 2019Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

A Phase 1 interventional study of GSK1278863 and Placebo in Wound Healing, sponsored by GlaxoSmithKline. Completed at 7 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-19.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 85 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
155th of 322
65 · median 60
Started
2013
with 19 others
Phase 1
19 of 381
3 open now
Registered
89th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 155th largest by enrollment of the 322 interventional ones that give a count, is one of 20 that started in 2013, is one of 19 in phase 1, and was the 89th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, single-blind (subjects and investigators will be blinded, GSK internal personnel will not be blinded), parallel-group, two part (Part A, Part B) trial in healthy volunteers and subjects with diabetic foot ulcers. Part A is designed to evaluate single applications of GSK1278863 in one cohort of healthy volunteers (intact skin) and approximately 3 cohorts of diabetic subjects. Part B is designed to evaluate first single, and then repeat applications of GSK1278863 in diabetics, both in the clinic and by subjects at home. Part B will include approximately 3 cohorts in which the concentration of drug applied will be determined by pharmacokinetic data from Part A and earlier cohorts in Part B.

03

Conditions studied

  • Wound Healing

Keywords

  • diabetic foot ulcer
  • pharmacodynamics
  • pharmacokinetics
  • ischemic
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Healthy Volunteers (Part A Cohort 1)

  • (ALT), alkaline phosphatase and \<=1.5xupper limit of normal () (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • [Single] interval (QTc) \< 450 millisecond (msec).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and (ECGs). A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with (Hb) values higher than ULN the normal range should always be excluded from enrollment.
  • Male or female between 18 and 90 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of non- ( or pre-menopausal females with a documented tubal ligation or hysterectomy). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods in the protocol.
  • Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol.

Inclusion Criteria - DFU Subjects must meet healthy volunteer inclusion criteria and the following

  • Diagnosed with Type I or Type II diabetes mellitus.
  • Glycosylated haemoglobin () \<=12%.
  • QTc \< 480 msec in subjects with bundle branch block.
  • Lower extremity diabetic foot ulcer of 30 to 364 days' duration.
  • DFU between 1 centimeter squared (cm \^2) and 20 cm\^2 at screening.
  • Presence of at least one DFU that meets all of the following criteria: (a). Ulcer has been diagnosed as a full-thickness, neuropathic DFU and is located at or distal to the malleolus (excluding ulcers between the toes but including those of the heel). (b). There is a minimum 2 cm margin between the qualifying study ulcer and any other ulcers on the specified foot. (c). Ulcer size (area) >=1 cm\^2 and \<=12 cm\^2 (post-debridement at time of randomization). (d). Wagner Grade 1. (e). Depth \<=5 millimeter (mm) with no capsule, tendon or bone exposed and no tunneling, undermining, or sinus tracts. Note: If the subject has more than one qualifying DFU, the ulcer designated as the study ulcer will be at the discretion of the Investigator. Non-study ulcers being treated during the course of the study will be treated with moist wound therapy Standard of Care (SOC) identified under this study.
  • Adequate vascular perfusion of the affected limb within 30 days of screening, as defined by at least one of the following: (a) Transcutaneous oxygen partial pressure (TcPO2) >35 millimeter of mercury (mmHg). (b) Ankle-Brachial Index (ABI) >=0.6 and \<=1.2, confirmed by TcPO2 >35 mmHg. (c) Toe pressure (plethysmography) >50 mmHg. (d) Doppler ultrasound (biphasic or triphasic waveforms) consistent with adequate blood flow to the affected extremity, as determined by SOC.

Exclusion Criteria - Healthy Volunteers (Part A Cohort 1)

  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of within 5 years of Screening or those with a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
  • A history of drug or alcohol abuse, or a history of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mililiter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • A positive test for (HIV) antibody.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives (whichever is longer).
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
  • Pregnant females as determined by positive urine human chorionic gonadotropin test at screening or prior to dosing.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated. Exclusion Criteria - DFU Subjects

Healthy volunteer exclusions apply to DFU subjects in addition to the following:

  • Subjects with ulcers accompanied by infected cellulitis, osteomyelitis, or clinical signs or symptoms of infection, Gangrene on any part of affected limb, Active Charcot's foot on the study limb, Planned vascular surgery, angioplasty or thrombolysis, Ulcers involving exposure of tendon, bone, or joint capsule (It is acceptable to have ulcers extending through the dermis and into subcutaneous tissue with presence of granulation tissue), Ulcers due to non-diabetic etiology.
  • Any unstable vascular syndromes (such as (TIA), cerebrovascular accident (CVA), unstable angina, acute myocardial infarction (MI) or acute coronary syndrome event (ACS) and/or any major changes (per investigator's judgment) to related medications within 6 months prior to randomization.
  • History or malignancy within 5 years of screening or those with a strong family history of cancer (e.g. familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
  • Other cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the Investigator or the GSK Medical Monitor, not stabilized or may otherwise impact the results of the study.
  • Patients with active treatment for retinal neovascularization (e.g., diabetic proliferative retinopathy or age related macular degeneration) within 6 months of randomization.
  • Patients undergoing hemodialysis.
  • History of venous thrombosis defined as deep vein thrombosis, pulmonary embolism or other venous thrombotic condition within 1 year prior to screening.
  • Active peptic, duodenal, or esophageal ulcer disease or any gastrointestinal bleeding, within 1 year prior to screening.
  • Subjects with a count \<100,000/mm\^3 at screening.
  • Subjects with an (INR) >1.5 at screening.
  • Subjects with a hemoglobin level above the gender-specific upper limit of normal at screening.
  • Subjects with a history of non-traumatic joint inflammation (with the exception of inflammation due to osteoarthritis).
  • Patients with known pulmonary hypertension.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Cohort 1 Part A

    Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 2 Part A

    Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 3 Part A

    Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 4 Part A

    Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 5 Part B

    Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 6 Part B

    Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

    Drug: GSK1278863 · Drug: Placebo

  • Experimental
    Cohort 7 Part B

    Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

    Drug: GSK1278863 · Drug: Placebo

Interventions

  • White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

  • DrugPlacebo

    White to off-white smooth ointment for topical application as single or repeat doses.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Single Dose Administration (Part A)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.

    Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  2. Number of Participants With AEs and SAEs Following Repeat Dose Administration (Part B)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.

    Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  3. Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A)

    ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.

    Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  4. Number of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B)

    ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.

    Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  5. Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Single Dose Administration (Part A)

    Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Day 1 (pre-dose and 48 hours) of Periods 1 and 2

  6. Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Repeat Dose Administration (Part B)

    Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Days 1 and 7 (pre-dose), Day 14 (24 hours)

  7. Number of Participants With Abnormal Nurse/Physician Observation (Part A)

    A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed.Since data was not collected, no analysis was performed.

    Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  8. Number of Participants With Abnormal Nurse/Physician Observation (Part B)

    A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed. Since data was not collected, no analysis was performed.

    Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

  9. Number of Participants With Hematology Values Outside the Clinical Concern Range (Part A)

    Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, absolute neutrophil count (ANC), monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Day 1 (pre-dose)

  10. Number of Participants With Hematology Data Outside the Clinical Concern Range (Part B)

    Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, neutrophils, monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Day 1 (pre-dose)

  11. Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part A)

    Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Day 1 (pre-dose and 48 hours) in period 1; Day 1 (48 hours) in period 2

  12. Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part B)

    Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

    Time frame: Days 1 and 7 (pre-dose) and Day 14 (24 hours)

  13. Maximum Observed Concentration (Cmax) of GSK1278863 (Part A)

    The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose

  14. Cmax of GSK1278863 (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

  15. Time of Occurrence of Cmax (Tmax) of GSK1278863 (Part A)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose

  16. Tmax of GSK1278863 (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

  17. Apparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose

  18. t1/2 of GSK1278863 (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

  19. Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose

  20. Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

  21. Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose

  22. AUC(0-inf) of GSK1278863 (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

  23. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose

  24. AUC(0-t) of GSK1278863 (Part B)

    The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

    Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14

07

Results

Posted Aug 19, 2019

Participant flow

This was a randomized, placebo-controlled, single-blind, parallel-group, two part (Part A and Part B) study in healthy volunteers (HVT) and participants with diabetic foot ulcer (DFU).

Participant flow — Overall Study
MilestonePlacebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
Started4395534264
Completed3135333232
Not completed126020132
Withdrew: Adverse event000000101
Withdrew: Protocol violation002000000
Withdrew: Protocol defined stopping criteria113010000
Withdrew: Lost to follow-up001000001
Withdrew: Investigator discretion000010010
Withdrew: Withdrew consent010000020

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Single Dose Administration (Part A)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.

Time frame:
Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Single Dose Administration (Part A)
ParticipantsPlacebo HVT (Cohort 1)A/B (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)C (Cohort 2)D (Cohort 3)E (Cohort 4)
AEs231021
SAEs000001
PrimaryNumber of Participants With AEs and SAEs Following Repeat Dose Administration (Part B)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.

Time frame:
Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Reported as:
Number · Participants
Number of Participants With AEs and SAEs Following Repeat Dose Administration (Part B)
ParticipantsPlacebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
AEs252
SAEs101
PrimaryNumber of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A)

ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.

Time frame:
Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Reported as:
Number · Participants
Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A)
ParticipantsPlacebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A)000000
PrimaryNumber of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B)

ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.

Time frame:
Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Reported as:
Number · Participants
Number of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B)
ParticipantsPlacebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
Number of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B)000
PrimaryNumber of Participants With Vital Sign Data Outside Clinical Concern Range Following Single Dose Administration (Part A)

Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Day 1 (pre-dose and 48 hours) of Periods 1 and 2
Reported as:
Number · Participants
Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Single Dose Administration (Part A)
ParticipantsPlacebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
DBP Period 2; Day 1; 48 hours; Low; n=4,1,0,5,0,300—0—0
DBP Period 2; Day 1; 48 hours; High; n=4,1,0,5,0,301—0—1
SBP; Period 1; Day 1;pre-dose;Low;n=4,3,9,5,5,3000000
SBP; Period 1; Day 1;pre-dose;High;n=4,3,9,5,5,3000210
SBP; Period 1; Day 1;48 hours;Low;n=4,3,8,5,4,3000000
SBP; Period 1; Day 1;48 hours;High;n=4,3,8,5,4,3000201
SBP; Period 2; Day 1;pre-dose;Low;n=4,2,0,5,0,300—0—0
SBP; Period 2; Day 1;pre-dose;High;n=4,2,0,5,0,300—1—0
SBP; Period 2; Day 1;48 hours;Low;n=4,1,0,5,0,300—0—0
SBP; Period 2; Day 1;48 hours;High;n=4,1,0,5,0,300—1—1
PrimaryNumber of Participants With Vital Sign Data Outside Clinical Concern Range Following Repeat Dose Administration (Part B)

Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Days 1 and 7 (pre-dose), Day 14 (24 hours)
Reported as:
Number · Participants
Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Repeat Dose Administration (Part B)
ParticipantsPlacebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
DBP,Day 1,pre-dose,Low,n=4,26,4000
DBP,Day 1,pre-dose,High,n=4,26,4010
SBP,Day 1,pre-dose,Low, n=4,26,4000
SBP,Day 1,pre-dose,High, n=4,26,4130
SBP,Day 7,pre-dose,Low, n=4,25,4000
SBP,Day 7,pre-dose,High, n=4,25,4020
SBP,Day 14,24 H,Low, n=3,22,1000
SBP,Day 14,24 H,High, n=3,22,1030
PrimaryNumber of Participants With Abnormal Nurse/Physician Observation (Part A)

A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed.Since data was not collected, no analysis was performed.

Time frame:
Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

No measurements were reported for this outcome.

PrimaryNumber of Participants With Abnormal Nurse/Physician Observation (Part B)

A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed. Since data was not collected, no analysis was performed.

Time frame:
Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])

No measurements were reported for this outcome.

PrimaryNumber of Participants With Hematology Values Outside the Clinical Concern Range (Part A)

Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, absolute neutrophil count (ANC), monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Day 1 (pre-dose)
Reported as:
Number · Participants
Number of Participants With Hematology Values Outside the Clinical Concern Range (Part A)
ParticipantsPlacebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Total ANC,Day 1,pre-dose,Low011000
Total ANC,Day 1,pre-dose,High000000
PrimaryNumber of Participants With Hematology Data Outside the Clinical Concern Range (Part B)

Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, neutrophils, monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Day 1 (pre-dose)
Reported as:
Number · Participants
Number of Participants With Hematology Data Outside the Clinical Concern Range (Part B)
ParticipantsPlacebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
Lymphocytes, Day 1,pre-dose,Low010
Lymphocytes, Day 1,pre-dose,High000
PrimaryNumber of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part A)

Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Day 1 (pre-dose and 48 hours) in period 1; Day 1 (48 hours) in period 2
Reported as:
Number · Participants
Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part A)
ParticipantsPlacebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Glucose,Day1,P1,pre-dose,low,n=4,3,9,5,5,3000000
Glucose,Day1,P1,pre-dose,high,n=4,3,9,5,5,3000010
Glucose,Day1,P1,48 H,low,n=4,3,8,5,4,3000000
Glucose,Day1,P1,48 H,high,n=4,3,8,5,4,3000001
Glucose,Day1,P2,48 H,low,n=4,1,0,5,0,300—0—0
Glucose,Day1,P2,48 H,high,n=4,1,0,5,0,300—1—2
PrimaryNumber of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part B)

Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Time frame:
Days 1 and 7 (pre-dose) and Day 14 (24 hours)
Reported as:
Number · Participants
Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part B)
ParticipantsPlacebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
Glucose,Day1,pre-dose,Low,n=4,26,4000
Glucose,Day1,pre-dose,High,n=4,26,4051
Glucose,Day7,pre-dose,Low,n=4,24,4000
Glucose,Day7,pre-dose,High,n=4,24,4072
Glucose,Day14,24H,Low,n=3,23,2000
Glucose,Day14,24H,High,n=3,23,2290
PrimaryMaximum Observed Concentration (Cmax) of GSK1278863 (Part A)

The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Observed Concentration (Cmax) of GSK1278863 (Part A)
Nanograms per milliliter (ng/mL)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Maximum Observed Concentration (Cmax) of GSK1278863 (Part A)NA ± NANA ± NANA ± NANA ± NA
PrimaryCmax of GSK1278863 (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · ng/mL
Cmax of GSK1278863 (Part B)
ng/mLR1r (Cohort 5)
Cmax of GSK1278863 (Part B)NA ± NA
PrimaryTime of Occurrence of Cmax (Tmax) of GSK1278863 (Part A)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Reported as:
Mean · Hour
Time of Occurrence of Cmax (Tmax) of GSK1278863 (Part A)
HourA/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Time of Occurrence of Cmax (Tmax) of GSK1278863 (Part A)NA ± NANA ± NANA ± NANA ± NA
PrimaryTmax of GSK1278863 (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · Hour
Tmax of GSK1278863 (Part B)
HourR1r (Cohort 5)
Tmax of GSK1278863 (Part B)NA ± NA
PrimaryApparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Reported as:
Mean · Hour
Apparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A)
HourA/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Apparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A)NA ± NANA ± NANA ± NANA ± NA
Primaryt1/2 of GSK1278863 (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · Hour
t1/2 of GSK1278863 (Part B)
HourR1r (Cohort 5)
t1/2 of GSK1278863 (Part B)NA ± NA
PrimaryLag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Reported as:
Mean · Hour
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A)
HourA/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A)NA ± NANA ± NANA ± NANA ± NA
PrimaryLag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · Hour
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B)
HourR1r (Cohort 5)
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B)NA ± NA
PrimaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Reported as:
Mean · hour*nanograms/milliliter
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A)
hour*nanograms/milliliterA/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A)NA ± NANA ± NANA ± NANA ± NA
PrimaryAUC(0-inf) of GSK1278863 (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · hour*nanograms/milliliter
AUC(0-inf) of GSK1278863 (Part B)
hour*nanograms/milliliterR1r (Cohort 5)
AUC(0-inf) of GSK1278863 (Part B)NA ± NA
PrimaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
Reported as:
Mean · hour*nanograms/milliliter
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A)
hour*nanograms/milliliterA/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A)NA ± NANA ± NANA ± NANA ± NA
PrimaryAUC(0-t) of GSK1278863 (Part B)

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

Time frame:
Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Reported as:
Mean · hour*nanograms/milliliter
AUC(0-t) of GSK1278863 (Part B)
hour*nanograms/milliliterR1r (Cohort 5)
AUC(0-t) of GSK1278863 (Part B)NA ± NA

Adverse events

Collected over SAEs and non-serious AEs were collected from start of study treatment through the final follow-up visit each of Part A {up to a maximum of 75 days (start of study treatment through final follow up 2 [28-32 days post last dose])} and B {up to a maximum of 53 days (start of study treatment through final follow up 2 [28-32 days post last dose])}. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo HVT (Cohort 1)0/4 (0%)0/4 (0%)1/4 (25%)
A/B (Cohort 1)0/9 (0%)0/9 (0%)2/9 (22.2%)
Placebo DFU SD (Cohort 2, 3, 4)0/3 (0%)0/3 (0%)1/3 (33.3%)
C (Cohort 2)0/5 (0%)0/5 (0%)0/5 (0%)
D (Cohort 3)0/5 (0%)0/5 (0%)0/5 (0%)
E (Cohort 4)0/3 (0%)1/3 (33.3%)1/3 (33.3%)
Placebo DFU RD (Cohort 5)0/4 (0%)1/4 (25%)1/4 (25%)
R1r (Cohort 5)0/26 (0%)0/26 (0%)0/26 (0%)
Sr (Cohort 5)0/4 (0%)1/4 (25%)1/4 (25%)
Most frequent serious events
Most frequent serious events
EventPlacebo HVT (Cohort 1)A/B (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)C (Cohort 2)D (Cohort 3)E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
OsteomyelitisInfections and infestations0/40/90/30/50/51/31/40/260/4
Arthritis bacterialInfections and infestations0/40/90/30/50/50/31/40/260/4
Skin ulcerSkin and subcutaneous tissue disorders0/40/90/30/50/50/30/40/261/4
Most frequent other events
Most frequent other events
EventPlacebo HVT (Cohort 1)A/B (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)C (Cohort 2)D (Cohort 3)E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)
Pain in extremityMusculoskeletal and connective tissue disorders0/40/90/30/50/51/31/40/260/4
Nasal congestionRespiratory, thoracic and mediastinal disorders0/41/91/30/50/50/30/40/260/4
Infected skin ulcerInfections and infestations0/40/90/30/50/50/31/40/261/4
PruritusSkin and subcutaneous tissue disorders1/41/90/30/50/50/30/40/260/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)Total
Mean42.5 ± 14.2053.0 ± 8.7244.4 ± 15.2752.6 ± 5.9059.2 ± 7.6648.3 ± 11.9350.0 ± 10.4255.5 ± 6.1355.5 ± 5.2651.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)Total
Female1030001319
Male336553323354
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo HVT (Cohort 1)Placebo DFU SD (Cohort 2, 3, 4)A/B (Cohort 1)C/C (Cohort 2)D (Cohort 3)E/E (Cohort 4)Placebo DFU RD (Cohort 5)R1r (Cohort 5)Sr (Cohort 5)Total
African American/African Heritage (Her.)21411006116
Japanese/East Asian Her./South East Asian Her.0000000101
White225443419346
08

Study locations

7 sites
  • GSK Investigational Site
    Castro Valley, California 94546, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Pinellas Park, Florida 33782, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
  • GSK Investigational Site
    Providence, Rhode Island 02903, United States
  • GSK Investigational Site
    Dallas, Texas 75390, United States
09

References and documents

Publications

  • Olson E, Mahar KM, Morgan L, Fillmore C, Holland C, Lavery L. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers. Clin Pharmacol Drug Dev. 2019 Aug;8(6):765-778. doi: 10.1002/cpdd.654. Epub 2019 Feb 5. PubMed 30720931 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Feb 2017, 43 months.

Results were first posted in Aug 2019, 2 years 6 months after primary completion.

Of 26 phase 1 interventional studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 43. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2013
First posted
Apr 15, 2013
StartActual
Jun 17, 2013
Primary completionActual
Feb 10, 2017
CompletionActual
Feb 10, 2017
Results first posted
Aug 19, 2019
Last update
Aug 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01831804
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 15, 2013
Start date
Jun 17, 2013
Primary completion
Feb 10, 2017
Completion
Feb 10, 2017
Results posted
Aug 19, 2019
Last update
Aug 19, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion